Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Becoming Important Phase I Player (Asia)

This article was originally published in PharmAsia News

Executive Summary

Global pharmaceutical companies are increasingly conducting clinical trial development from the basics upward in Asia, rather than simply using Asia's outsourcing industry for late-stage clinical work. As a result phase-I clinical trials are becoming more prevalent in China, South Korea, Japan, and India, alongside late-stage trials more often underway in these developing countries. Shirley Suresh of Singapore Clinical Research says that comparing global data from full-spectrum clinical trials is more scientifically effective than comparing data from "bridging studies." The U.S.-based FDA concurs, notes Suresh. Suresh says that Singapore has been encouraging companies to develop research from the phase-I level, and has been attracting international attention. Singapore also has a mixed Asia population, and so its clinical trial data is being accepted in South Korea, in some cases in Japan, and by other countries, says Suresh. Japan's recent lowering of regulatory hurdles to clinical trials should boost the volume of global companies conducting clinical research in Japan in 2008 and 2009. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066369

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel